Traws Pharma, Inc. Q2 FY2022 earnings call

• Progress on narazaciclib phase 1 trials: Completed four dosing cohorts in two phase 1 alchemer solid tumor studies, safety data favorable; amended protocol to collect pharmacodynamic data using DiviTum assay. - Rigosertib investigator-sponsored programs: Ongoing trials in melanoma and KRAS mutated non-small cell lung cancer; promising preliminary data. - Financial position: Cash and cash equivalents of $46.5 million as of June 30, 2022; R&D expenses $2 million, G&A expenses $2.1 million for Q2 2022; net loss $4 million.

No distinct product segments with revenue contributions discussed in the transcript.

• Expect to identify recommended phase 2 dose for narazaciclib before end of 2022. - Plan to announce additional data from Rigosertib phase 1/2 KRAS mutated non-small cell lung cancer trial via abstract submitted to ESMO meeting in September. - Anticipate identifying Rigosertib optimal phase 2 dose in the second half of the year.

Q: Given progress on narazaciclib, should we interpret dose cohorts six to seven as likely maximum tolerated doses?

A: Mark Gelder stated they have not seen dose limiting toxicity through cohort four, incorporated DiviTum assay, and can't predict exactly when MTD will be reached but are hopeful it's before end of year.

Q: More color on phase 2 basket trial plans, including other indications and combinations?

A: Mark Gelder mentioned plans in breast cancer (likely with anti-estrogen), mantle cell lymphoma, and other indications; exact trial designs not finalized yet but moving forward with promising preclinical findings.

Q: Timeframe for phase 2 start for narazaciclib?

A: Steve Fruchtman said can't predict exactly but suspect recommended phase 2 dose may be known by end of year, then will rapidly move to open bucket trials for various indications